A novel c-Met targeting antibody drug conjugate for NSCLC

被引：1
|
作者：
Li, Lingna
Fells, Cathrine
Guo, Julia
Muyot, Pia
Gros, Edwige
Zhang, Yanliang
Sun, Yingqing
Zhang, Hong
Fu, Yanwen
Zhu, Tong
Cao, Jian
Kaufmann, Gunnar
Chen, Gang
Miao, Zhenwei
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3897
引用
收藏
页数：3
相关论文
共 50 条
  • [21] BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET
    Li, Zhuolin
    Shang, Chengzhang
    Guan, Xuewa
    Han, Zhenyan
    An, Gao
    Zhang, Ellen
    Lin, Qingcong
    Yang, Yi
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
    Heist, R. S.
    Motwani, M.
    Naumovski, L.
    Wu, J.
    Bach, B. A.
    Lu, X.
    Kelly, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload
    Lai, Katharine C.
    Muvaffak, Asli
    Li, Min
    Themeles, Marian
    Sikka, Surina
    Donahue, Kerry
    Hicks, Stuart W.
    Romanelli, Angela
    Chittenden, Thomas
    CANCER RESEARCH, 2017, 77
  • [24] A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
    Cazes, Alex
    Betancourt, Oscar
    Esparza, Edgar
    Mose, Evangeline S.
    Jaquish, Dawn
    Wong, Eric
    Wascher, Alexis A.
    Tiriac, Herve
    Gymnopoulos, Marco
    Lowy, Andrew M.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 2100 - 2110
  • [25] Mechanisms of EGFR and c-Met inhibitor resistance in NSCLC
    Fong, Jason T.
    Puri, Neelu
    CANCER RESEARCH, 2011, 71
  • [26] C-Met, a marker of resistance to EGFR inhibitors in NSCLC
    Engelman, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 22 - 22
  • [27] SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met
    Tong, Mengya
    Gao, Mingzhao
    Xu, Yongping
    Fu, Li
    Li, Yun
    Bao, Xubin
    Fu, Haoyu
    Quan, Haitian
    Lou, Liguang
    CANCER SCIENCE, 2019, 110 (11) : 3584 - 3594
  • [28] Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report
    Fox, Daniel A.
    Tran, Christine
    Blot, Vincent
    Hong, David S.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (02) : 108 - 112
  • [29] Targeting the c-Met signaling pathway in cancer
    Peruzzi, Benedetta
    Bottaro, Donald P.
    CLINICAL CANCER RESEARCH, 2006, 12 (12) : 3657 - 3660
  • [30] Predicting tissue c-Met status using plasma soluble c-Met levels in patients with advanced NSCLC
    Gao, H.
    Chen, Z.
    Li, A.
    Yang, J.
    Zhang, X.
    Xie, Z.
    Su, J.
    Lin, J.
    Li, Y.
    Wu, Y. -L.
    Dong, Z.
    ANNALS OF ONCOLOGY, 2015, 26 : 10 - 10
12345